☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
merck
Merck Commences P-IIb/III (BRUNELLO) Clinical Evaluation of Restoret to Treat Diabetic Macular Edema (DME)
September 4, 2024
Merck Discontinues P-III (KEYNOTE-867 and KEYNOTE-630) Studies Evaluating Keytruda for Cancer Treatment
August 29, 2024
Merck Begins the P-III Clinical Evaluation of Bomedemstat to Treat Essential Thrombocythemia
August 28, 2024
Merck Reports the Acquisition of Curon Biopharmaceutical’s CN201 to Treat Various B-Cell Related Diseases
August 12, 2024
Merck Discontinues the P-III (KeyVibe-008) Study of Vibostolimab and Keytruda to Treat Extensive-Stage Small Cell Lung Cancer
August 9, 2024
Merck and Daiichi Sankyo Expand their Partnership to Include Development of MK-6070
August 6, 2024
Load more...
Back to Home